SOURCE: TriMarkPublications.com

TriMarkPublications.com

August 15, 2013 13:45 ET

Global Companion Biomarker Market to Catapult to $319 Million by 2018

NEW YORK, NY--(Marketwired - Aug 15, 2013) -  TriMarkPublications.com cites in its newly published "Companion Biomarkers in Drug Development" report that the global companion biomarker market will catapult to $319 million by 2018. For more information, visit: http://www.trimarkpublications.com/companion-biomarkers-in-drug-development/.

Companion biomarkers can be categorized into four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. Oncology is the largest segment, commanding 30% of the market. Market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points. Using companion biomarkers, the $883 billion global pharmaceutical market yields safer and more efficacious drug products, reduces clinical trial and development costs, improves post-marketing safety profiles and salvages therapies that otherwise would not be granted approval.

The "Companion Biomarkers in Drug Development" report covers:

  • DNA Microarrays
  • Antibody Microarrays
  • Peptide Microarrays
  • Peptide MHC Microarrays
  • Tissue Microarrays
  • GeneChip Probe Array Technology
  • Multiple Reaction Monitoring Assays (MRMs)
  • C-KIT (CD117) Expression
  • CYP2C19 Variants
  • CYP2C9 Variants
  • CYP2D6 Variants
  • Kidney Toxicity
  • Hepatotoxicity

The "Companion Biomarkers in Drug Development" report examines companies manufacturing companion biomarker equipment and supplies in the world. Companies covered include: Abbott, Accelrys, Almac, Ananomouse, ArrayIt, AstraZeneca, Axontologic, BD, Bioalma, BioCat, BioData, Biodesix, BioForce Nanosciences, BioGenex, BioMérieux, Bio-Rad, Biotrin, BioWisdom, Caliper Life, Caprion Proteomics, Cepheid, Clontech, Corimbia, Covance, CyVera, Dako, DiagnoSwiss, DNAStar, Eli Lilly, ePitope Informatics, Eurogentec, Fujitsu, GEcare, Gene Network, Genedata, GeneStudio, Geneva Bioinformatics, GenomeQuest, Genomining, Genzyme, Geospiza, Golden Helix, Grace Bio-Labs, High Throughput, Imgenex, INCOGEN, InforSense, Ingenuity, Integromics, Ipsen, Koada Technology, KOOPrime, LINCO, Luminex, MDS, Meso Scale Discovery, MicroDiscovery, Millennium, MiraiBio, Molecular Connections, Monograms, Multimetrix, NetGenics, NextGen, Nonlinear Dynamics, Novartis, Osmetech, Oxonica, Panomics, Partek, Perlegen, PharmaSeq, Predictive Patterns, Proceryon, ProteinOne, Proteome, Radix BioSolutions, RayBiotech, Reel Two, Rescentris, Rosetta Biosoftware, SAS, Semantx Life, Softberry, SoftGenetics, Spotfire, SPSS, Sun Microsystems, SurroMed, Tepnel, Teranode, TG Services, Thermo Fisher, TimeLogic, Tyrian, ViaLogy, Wyeth, Zeus and Zyagen.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit: http://www.trimarkpublications.com/companion-biomarkers-in-drug-development/.

About TriMarkPublications.com

TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit http://www.trimarkpublications.com.

Important Notice

The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information